Neri Master Antibiotics Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 2 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
About Neri Master Antibiotics
Neri Master Antibiotics Private Limited (NMAPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 August 2022 (Two years and five months 13 days old ). Its registered office is in Solan, Himachal Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Biro Bibi and Rajak Mohammad serve as directors at the Company.
Company Details
-
Location
Solan, Himachal Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290HP2022PTC009525
-
Company No.
009525
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Aug 2022
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Neri Master Antibiotics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Biro Bibi
|
Director | 23-Aug-2022 | Current |
|
Rajak Mohammad
|
Director | 23-Aug-2022 | Current |
Financial Performance of Neri Master Antibiotics.
Neri Master Antibiotics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neri Master Antibiotics?
Unlock access to Neri Master Antibiotics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Neri Master Pharma Private LimitedBiro Bibi and Rajak Mohammad are mutual person
-
Lukman Master Cosmetics Private Limited
Rajak Mohammad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neri Master Antibiotics?
Neri Master Antibiotics has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neri Master Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neri Master Antibiotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.